Relapse Prevention for Suicidal Dually Diagnosed Youths (CBT-RP)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00589641
Recruitment Status : Completed
First Posted : January 10, 2008
Last Update Posted : July 10, 2014
UConn Health
University of North Carolina, Chapel Hill
University of North Carolina, Greensboro
Information provided by (Responsible Party):
Duke University

Brief Summary:
The purpose of this study is to develop, refine, and pilot test an augmenting cognitive behavior relapse prevention intervention (CBT-RP) for suicidal, depressed, and alcohol/substance abusing adolescents. No hypotheses are being tested, but it is expected that CBT-RP in addition to treatment as usual will result in improved outcomes relative to treatment as usual alone.

Condition or disease Intervention/treatment Phase
Suicide, Attempted Suicide, Ideation Depression Substance Abuse Behavioral: CBT-RP (relapse prevention) + Enhanced TAU Behavioral: Enhanced TAU Alone Phase 1

Detailed Description:

Suicide attempts are not only associated with increased likelihood of eventual death by suicide (Lonnqvist & Ostano, 1991), increased risk of repeat suicidal behavior (Goldston et al., 1999; Leon et al., 1989), and risk of physical injury, but suicidality is also one of the primary reasons for psychiatric emergencies and psychiatric hospitalizations (Peterson et al., 1996). Suicide attempters, particularly repeat attempters, often have histories of both depression and substance abuse problems. Cognitive behavioral interventions have been shown to have promise in the treatment of depression (Brent et al., 1997), suicidality (Henriques, Beck, & Brown, 2002), and substance use disorders in youths (Dennis et al., in press; Kaminer et al., 2002). Relapse prevention approaches have been shown to have utility with substance abusing adults (Witkiewitz & Marlatt, 2004), and conceptually are well suited for the prevention of both suicidal behavior and substance use among young people. The purpose of the research outlined in this application is therefore to develop, refine, and test a cognitive behavioral relapse prevention intervention (CBT-RP) for dually diagnosed suicidal adolescents and young adults.

The specific aims of this research are as follows:

  1. To develop and refine a cognitive behavioral relapse prevention treatment manual for suicidal adolescents and young adults with comorbid depressive and substance use disorders.
  2. To develop and pilot test procedures for training therapists to conduct CBT-RP. Methods for assessing therapist competence and adherence to the protocols, and certification standards will be developed and refined.
  3. To assess the feasibility of CBT-RP via monitoring of rates of recruitment and retention of subjects, monitoring of therapist adherence and deviation from the protocols, and monitoring of adverse events.
  4. To assess the feasibility of the assessment methods and outcome measures to be used in this study as reflected in burden in completing assessments over the course of treatment.
  5. To estimate the degree of change and variability of response to CBT-RP relative to no CBT-RP as an add-on treatment to Treatment as Usual (TAU) in the community on the primary outcomes of suicidal ideation, depressive symptoms, and substance use problem severity.
  6. To assess the acceptability of CBT-RP relative to no CBT-RP as an add-on treatment to TAU in the community as assessed qualitatively via exit interviews and quantitatively via ratings of patient satisfaction

There are four phases to this treatment development study: (1) initial manual and protocol development (not requiring human subject involvement); (2) piloting (and revision) of the manual by the investigators; (3) training and supervision of new therapists using the new intervention; and, (4) the pilot randomized controlled trial. We have completed the first phase of this study. Currently, we are involved in completing pilot testing and initiating training of new therapists with the protocol (n=12). A subsequent pilot randomized controlled trial will be used to examine feasibility and preliminary evidence of effects (and variability of effects) of CBT-RP as an augmenting intervention (n=36).

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 13 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Relapse Prevention for Suicidal Dually Diagnosed Youths
Study Start Date : July 2005
Actual Primary Completion Date : September 2010
Actual Study Completion Date : October 2010

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Suicide
U.S. FDA Resources

Arm Intervention/treatment
Experimental: CBT-RP + Enhanced TAU
CBT-RP augmenting relapse prevention intervention, in addition to enhanced treatment as usual, monthly check-ins, and monitoring
Behavioral: CBT-RP (relapse prevention) + Enhanced TAU
CBT-RP is an 20-week augmenting intervention. CBT-RP is based primarily on Alan Marlatt's cognitive behavioral relapse prevention model for substance abuse, but also includes motivational interviewing and mindfulness meditation approaches. Sessions are twice a week in first week, then weekly thereafter, with tapering to biweekly in the last 8 weeks depending on improvement. Participants also receive treatment as usual, and monthly check-ins regarding treatment use.
Active Comparator: Enhanced TAU (Treatment as Usual)
Treatment as usual in the community, monthly monitoring regarding service use and needs, monitoring
Behavioral: Enhanced TAU Alone
Treatment as usual in the community, monthly check-ins regarding treatment use or needs, and monitoring

Primary Outcome Measures :
  1. suicide ideation and behavior [ Time Frame: pre-treatment, 10 weeks, end of treatment, 3-month follow-up ]

Secondary Outcome Measures :
  1. depression severity, alcohol/cannabis abuse impairment [ Time Frame: pre-treatment, 10 weeks, end of treatment, 3 month follow-up ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   13 Years to 19 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Teenagers 13-19 living with parents, or foster parents, at least one of whom is English speaking and willing to participate
  • Participation in ongoing treatment in the community (or willing to accept a referral for treatment as usually delivered in the community)
  • Marijuana or alcohol use or dependence disorder
  • Depressive disorder (major depression, dysthymia, depressive disorder NOS)
  • High suicide risk as reflected in: (a) recent suicidal behaviors (suicide attempts, aborted attempts, interrupted attempts, or suicide plans) in last 4 weeks OR (b)lifetime history of suicidal behaviors together with current clinically significant suicidal ideation (measured on a self-report questionnaire)

Exclusion Criteria:

  • Substance Dependence Disorder other than alcohol or cannabis or nicotine
  • SUD severity such that higher (more intensive) level of treatment (e.g., residential, hospitalization) is needed
  • Psychiatric difficulty other than substance abuse, suicidality, or depression that needs to be the primary focus of treatment (e.g., severe eating disorder or psychosis)
  • Evidence of mental retardation or poor receptive vocabulary as assessed with Peabody Picture Vocabulary Test

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00589641

United States, North Carolina
Duke Child and Family Study Center
Durham, North Carolina, United States, 27705
Sponsors and Collaborators
Duke University
UConn Health
University of North Carolina, Chapel Hill
University of North Carolina, Greensboro
Principal Investigator: David B Goldston, Ph.D. Duke University

Responsible Party: Duke University Identifier: NCT00589641     History of Changes
Other Study ID Numbers: Pro00006806
R34MH067904 ( U.S. NIH Grant/Contract )
First Posted: January 10, 2008    Key Record Dates
Last Update Posted: July 10, 2014
Last Verified: June 2010

Keywords provided by Duke University:
suicidal ideation and behavior
substance abuse

Additional relevant MeSH terms:
Substance-Related Disorders
Suicide, Attempted
Behavioral Symptoms
Self-Injurious Behavior
Chemically-Induced Disorders
Mental Disorders